Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Mizrahi on the Importance of Personalized Care in mCRC

April 24th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of personalized care in patients with metastatic colorectal cancer.

Dr. Ku on Role of Durvalumab in Gastric Cancer

April 24th 2019

Geoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of durvalumab in the treatment of patients with gastric cancer.

New VENTANA HER2 ISH DNA Assay Launches for Breast, Gastric Cancers

April 23rd 2019

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has launched to identify HER2 amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

Dr. Ciombor Discusses Role of Liquid Biopsies in CRC

April 22nd 2019

Kristen Ciombor, MD, MSCI, assistant professor of medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the role of liquid biopsies in colorectal cancer.

SM-88 May Fill Unmet Need in Pancreatic Cancer

April 22nd 2019

Marcus Smith Noel, MD, discusses the early promise of SM-88 in the metastatic pancreatic cancer treatment landscape.

Dr. Overman on Unmet Needs With Immunotherapy in mCRC

April 19th 2019

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses unmet needs with immunotherapy in metastatic colorectal cancer.

Tailored Approaches Offer Curative Potential to CRC Subsets

April 19th 2019

Michael J. Overman, MD, discusses an immunotherapy combination regimen in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.

Dr. Tempero on Role of Molecular Profiling in Pancreatic Cancer

April 18th 2019

Margaret A. Tempero, MD, director, University of California, San Francisco (UCSF) Pancreas Center, professor of medicine, Division of Hematology and Oncology, Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the role of molecular profiling in pancreatic cancer.

Dr. Fakih on Immunotherapy in MSS Colon Cancer

April 18th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of immunotherapy in patients with microsatellite stable (MSS) colon cancer.

Dr. Lee on Treatment of Newly Diagnosed mCRC

April 17th 2019

Michael S. Lee, MD, assistant professor of medicine, Department of Molecular Therapeutics, UNC Lineberger Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed metastatic colorectal cancer.

Dr. Eng Discusses the BEACON CRC Study in BRAF-Mutated CRC

April 17th 2019

Cathy Eng, MD, professor of gastrointestinal and medical oncology, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the BEACON CRC study in patients with BRAF-mutated colorectal cancer.

Dr. Mahipal on Maintenance Therapy in CRC

April 16th 2019

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses maintenance therapy in colorectal cancer (CRC).

Targeted Treatments Usher in Individualized Care in mCRC

April 15th 2019

Jonathan Mizrahi, MD, discusses recent pivotal data in colorectal cancer and its impact on personalized care in the treatment paradigm.

FDA Approvals Represent New Wave of Progress in Advanced HCC

April 15th 2019

Benjamin Leon Musher, MD, reflects on the progress that has been made in hepatocellular carcinoma and highlights promising combinations that are emerging in the space.

Genetic Testing Recommended for All Patients With Pancreatic Cancer

April 12th 2019

In a provisional clinical opinion, an expert panel convened by the American Society of Clinical Oncology has recommended that patients with pancreatic cancer undergo assessment of risk for hereditary syndromes that contribute to higher likelihood of pancreatic cancer.

Dr. Fakih on the Use of Regional Therapy in Colorectal Cancer

April 11th 2019

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of regional therapy in the treatment of patients with colorectal cancer (CRC).

Dr. Tempero on Importance of Germline Testing in Pancreatic Cancer

April 11th 2019

Margaret A. Tempero, MD, director of the Pancreas Center and the Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the importance of germline testing in pancreatic cancer.

Genetic Testing Essential to Advancing Pancreatic Cancer Paradigm

April 9th 2019

Margaret A. Tempero, MD, discusses the impact of FOLFIRINOX in the treatment of patients with metastatic pancreatic cancer and sheds light on the importance of molecular profiling in the space.

Dr. Marshall on HER2 Amplification in Colorectal Cancer

April 8th 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses HER2 amplification in colorectal cancer (CRC).

Dr. Kim on Role of Frontline Immunotherapy in Advanced HCC

April 8th 2019

Richard Kim, MD, assistant professor of oncology, University of South Florida College of Medicine, medical oncologist, Department of Gastrointestinal Oncology, Moffitt Cancer Center, discusses the role of frontline immunotherapy in patients with advanced hepatocellular carcinoma.